Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

Reuters

05-28

Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538491466"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538491466\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538491466?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538491466","market":"us","top_or_hot":-1,"title":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-28 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2yzZbT:1","article_id":"2538491466","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538491466","pubTimestamp":1748376346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor as Safe and Effective Opioid-Sparing Pain Management for Older Adults. NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc.  has announced the publication of a new clinical study assessing Caldolor  in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CPIX":"坎伯兰药业","BK4557":"大麻股"},"translate_title":"Cumberland Pharmaceuticals公布的研究证实Caldolor®可安全有效地治疗老年人阿片类药物疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPIX":0.9},"content_text":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    \n\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}